Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ELTX

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics logo

About Elicio Therapeutics Stock (NASDAQ:ELTX)

Advanced Chart

Key Stats

Today's Range
$10.20
$10.36
50-Day Range
N/A
52-Week Range
N/A
Volume
61,887 shs
Average Volume
142,069 shs
Market Capitalization
$168.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

Elicio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

ELTX MarketRank™: 

Elicio Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 774th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elicio Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Elicio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elicio Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elicio Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elicio Therapeutics has a P/B Ratio of 94.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.12% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Elicio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Elicio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.12% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 1.36%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Elicio Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for ELTX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    5 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    50.90% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 35.03% of the stock of Elicio Therapeutics is held by institutions.

  • Read more about Elicio Therapeutics' insider trading history.
Receive ELTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ELTX Stock News Headlines

BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
Elicio Therapeutics: Q2 Earnings Snapshot
See More Headlines

ELTX Stock Analysis - Frequently Asked Questions

Elicio Therapeutics, Inc. (NASDAQ:ELTX) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.03.

Elicio Therapeutics (ELTX) raised $40 million in an initial public offering on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

Top institutional investors of Elicio Therapeutics include Geode Capital Management LLC (0.76%), Mayflower Financial Advisors LLC (0.06%) and Raymond James Financial Inc. (0.04%).
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:ELTX
CIK
1555192
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$13.00
Potential Upside/Downside
+25.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.90 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-175.83%

Debt

Debt-to-Equity Ratio
5.09
Current Ratio
2.28
Quick Ratio
2.28

Sales & Book Value

Annual Sales
$2.30 million
Price / Sales
73.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.11 per share
Price / Book
94.36

Miscellaneous

Outstanding Shares
16,340,000
Free Float
8,022,000
Market Cap
$169.61 million
Optionable
Not Optionable
Beta
1.18
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ELTX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners